Clinical research
GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
In a flurry of weekend activity, oncology companies showcased the latest clinical and preclinical data for cancer therapies during the virtual American Association for Cancer Research meeting.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.
Regeneron Pharmaceuticals announced the results from its Phase III trial of recently infected asymptomatic COVID-19 patients for its REGEN-COV (casirivimab with imdevimab) antibody cocktail.
Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Bristol Myers Squibb announced topline data from the Phase III CheckMate -648 trial on Thursday, with positive results in esophageal cancer.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
PRESS RELEASES